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1. Introduction  
Complement was first discovered in 1889 as a bactericidal protein, distinct from heat stable 
antibodies present in normal serum. Since that time, it has been shown that the complement 
system is a biochemical cascade, comprised of more than 30 fluid phase and membrane-
associated proteins, normally present as inactive forms. The complement system can be 
activated by different sequential cascades of enzymatic reactions (described below) in which 
proteins are sequentially cleaved and activated. The resulting effector molecules, C3a and 
C5a (also known as anaphylatoxins) are the most potent complement activation products, 
showing diverse activities on many cell types ranging from chemoattraction to apoptosis. 
The main target cells carry specialized complement receptors through which anaphylatoxins 
participate in host defense, inflammatory processes, and immune responses.  
The complement system plays an essential role in innate immunity by defending the host 
against bacterial, viral, and parasitic invasion. Complement proteins promote opsonisation 
and/or phagocytosis and intracellular killing of these pathogens by immune effector cells 
such as macrophage and neutrophils. Complement proteins, particularly those of the 
classical pathway, aid in the processing of immune complexes and in protection against the 
development of immune complex diseases such as systemic lupus erythematosus (SLE). 
Recently, it has become evident that the complement system also regulates adaptive 
immunity involving B and T cells that help in the elimination of pathogens. Furthermore, 
the engagement of complement receptors on antigen-presenting cells (APC) and other 
immune cells leads to production of immunoregulatory cytokines. Not only is complement 
involved in innate and adaptive immunity, it is also involved in pathological conditions. For 
example, in allergic disease complement proteins participate in the development of an 
inflammatory reaction. The complement pathways are also activated in patients with sepsis, 
allergic rhinitis, allergic asthma, and allergic skin conditions such as urticaria. This chapter 
will outline how complement proteins, C3a and C5a, and their complement receptors 
regulate inflammation.  
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2. Complement system 
2.1 Complement activation pathways 
Pattern recognition receptors (PRRs) in the complement system such as specific antibody, 
C1q, C3, mannose-binding lectin (MBL), and ficolins recognize exogenous as well as 
endogenous pattern-associated molecular patterns (PAMPs) leading to the activation of 
complement (Wills-Karp, 2007).  The complement system can be activated by four different 
pathways: the classical, alternative, lectin and extrinsic protease pathway. Although each of 
these pathways is activated by distinct PRRs, they all culminate in activation of C3, the 
central step in complement activation.  
2.1.1 Classical pathway 
The classical pathway is activated when immune complexes are formed. These immune 
complexes are formed when antibodies (released during a humoral immune response 
(immunoglobulin (Ig)G or IgM)) bind to pathogens or other foreign and non-self antigens.  
The Fc portion of the antigen-antibody complex is engaged by the C1q molecule of the C1 
complex (a multimeric complex consisting of C1q, C1r and C1s molecules) leading to 
activation of C1s and C1r. C1 then cleaves C4 and C2 to form C3 convertase (C4bC2a; Figure 
1) (Wagner and Frank, 2010).  
C3 convertase enzyme activates C3, the most abundant complement protein found freely in 
blood plasma, by proteolytic cleavage. This reaction results in the generation of: (1) 
complement proteins C3a, C4a and C5a; (2) membrane attack complex (MAC) consisting of 
C5b, C6, C7, C8 and C9; and (3) opsonisation molecule C3b (Wagner and Frank, 2010; Wills-
Karp, 2007). 
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Fig. 1. Complement activation pathways 
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2.1.2 Lectin pathway 
The lectin pathway is initiated when PRRs, MBL, H-, M- and L-ficolin, recognize and bind 
sugar moieties on yeast, bacteria, parasites and viruses. In the circulation, these PRRs 
associate with MBL-associated serine protease 1 (MASP1), MASP2 and MASP3, and a 
truncated MASP2 known as MAP19. Binding of the MBL-MASP complex to pathogen 
results in the cleavage of C4 and C2 and the generation of a C3 convertase (C4bC2a; Figure 
1), similar to that of the classical pathway (Wagner and Frank, 2010).  
2.1.3 Alternative pathway 
The alternative pathway is triggered by carbohydrates, lipids and proteins found on 
pathogen. Slow and constant hydrolysis of circulating C3 (C3 tickover) and its interaction 
with complement factors B, and D leads to formation of a C3 convertase (C3bBb; Figure 1) 
(Wagner and Frank, 2010).  
2.1.4 Extrinsic protease pathway 
In addition to the above three pathways, a C3 independent pathway can also activate the 
complement system. An extrinsic protease pathway involves direct cleavage of C3 and C5 
by a series of proteolytic enzymes released by neutrophils and macrophages; and factors 
such as Kallikrein, plasmin and factor XIIa. Thrombin, a coagulation factor, can directly 
cleave C5 to generate biologically active C5a in C3-deficient mice in which C5 convertase 
cannot be formed (Ricklin et al., 2010).   
2.2 Complement proteins C3a, C4a and C5a 
The complement proteins, C3a, C4a and C5a, are components of the complement system 
that are produced from C3, C4 and C5, respectively, as part of the complement activation 
cascade. C3a is a 9 kiloDalton (kDa) peptide fragment released during selective proteolytic 
cleavage of the C3 ǂ chain by a C3 convertase of the classical or the alternative pathway. C4a 
is a 8.7 kDa peptide released from the ǂ chain of C4 by C2a cleavage in an early step of the 
classical pathway. C5a is an 11 kDa peptide released from the ǂ chain of C5 by action of 
either classical or alternative pathway C5 convertase (Ember and Hugli, 1997).  
Although C3a, C4a and C5a are genetically related, they have marked structural differences 
in their sequences. Only 13 residues are conserved between C3a, C4a and C5a molecules 
from several species examined. Six of the conserved residues are cysteines whose side 
chains participate in forming three intrachain disulfide linkages that stabilize the folded 
alpha-helical peptide chain. The three disulfide bonds in C3a are Cys 22-Cys 49, Cys 23-Cys 
56 and Cys 36-Cys 57. The four-helix bundle of C5a is stabilized by Cys 21-Cys 47, Cys 22-
Cys 54 and Cys 34-Cys 55 disulfide bonds. Further structural similarities include a flexible 
carboxyl terminal tail –L-G-L-A-R in C3a, -A/V-G/H-L-A/Q-R in C4a, and –M/I/V-Q-L-G-
R in C5a, which forms a helical turn connected by a short loop, which is important for 
effector functions of these proteins (Ember and Hugli, 1997).  
C3a, C4a and C5a are potent inflammatory peptides with diverse activities on many cell 
types. They act as chemoattractants for immune cells such as neutrophils, eosinophils, mast 
cells, and monocytes recruiting to sites of injury or inflammation. They also regulate 
vasodilation, increase the permeability of blood vessels, and induce smooth muscle 
contraction. Anaphylatoxin stimulation can induce oxidative burst in neutrophils, histamine 
release from mast cells and basophils, production of eosinophil cationic protein (ECP) from 
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eosinophils, and production of pro-inflammatory cytokines from monocytes, B cells and T 
cells. Characterization of the inflammatory activities of complement proteins indicate 
relative activities in the order of C5a>C3a>C4a on most tissues examined (Hugli, 1981).  
The complement proteins generated as a result of the complement activation damage host 
tissues. It is therefore obvious that control mechanisms are needed to tightly regulate these 
potent peptides and maintain homeostatic balance. Indeed, once C3a and C5a are cleaved 
from C3 and C5 respectively, they are rapidly degraded by plasma enzyme 
carboxypeptidases. The resulting C3a desArg lacks any pro-inflammatory activity; however, 
C5a desArg exhibits a reduced inflammatory activity of 1-10% compared with C5a. 
Interestingly, C3a desArg, also known as acylation stimulating protein (ASP), has been 
described as possessing metabolic hormone activity that drives triglyceride synthesis and 
glucose update. This suggests a regulatory role of C3a desArg in cell apoptosis and lipid 
metabolism (Cianflone et al., 1989).  
3. Complement receptors for C3a and C5a: C3aR, C5aR and C5L2 
The complement proteins C3a and C5a exert their pleiotropic effects by binding to a family 
of three receptors belonging to the G protein-coupled receptor (GPCR) superfamily. These 
receptors are the C3a receptor (C3aR), the C5a receptor (C5aR) and the C5a receptor-like 2 
(C5L2).   
3.1 C3a receptor (C3aR) 
C3aR is a membrane glycoprotein of approximately 54 kDa (Ames et al., 1996). This receptor 
displays high affinity for C3a with a dissociation constant (Kd) of about 1 nM, but not for 
C3a desArg or C5a (Crass et al., 1996).  Human platelets express a high molecular weight 
(95-105 kDa) variant of C3aR that binds C3a with Kd of 8 x 10-10 M.   
3.1.1 Structure 
As a GPCR, C3aR contains seven transmembrane domains within its 482 amino acids 
sequence. C3aR distinctively possesses a large second extracellular loop between the fourth 
and fifth transmembrane domain that is indispensable for ligand binding. This loop contains 
175 amino acid residues; in most GPCR the corresponding extracellular loop is 30-40 amino 
acids long. Sulfation of tyrosine 174 in this loop is essential for binding C3a (Chao et al., 
1999). The genes encoding C3aR have been mapped to p13.2-3 of chromosome 12 in humans 
and 6F1 in mouse (Hollmann et al., 1998). C3aR displays 50-60% homology between various 
species, with 65% sequence identity between human and murine counterparts (Hollmann et 
al., 1998).  
3.1.2 Expression 
C3aR is expressed on cells of myeloid origin, including monocytes/macrophages, 
neutrophils, eosinophils, basophils, mast cells, dendritic cells and microglia. Additionally, 
C3aR is also expressed on non-myeloid cells, such as astrocytes, endothelial cells, epithelial 
cells, smooth muscle cells, and activated T cells. One paper has described the receptor’s 
expression on human tonsillar B cells; while others have confirmed the absence of C3aR on 
human B cells. The receptor is also expressed in tissues from lung, liver, kidney, brain, heart, 
muscle and, testis. 
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3.1.3 Biological role 
C3aR mediates chemotaxis of eosinophils (Daffern et al., 1995), mast cells (Nilsson et al., 
1996), dendritic cells (Gutzmer et al., 2004) and monocytes, but not neutrophils (Daffern et 
al., 1995). It can also trigger oxidative burst in macrophages, neutrophils and eosinophils 
(Burg et al., 1996). In addition, basophils (Bischoff et al., 1990) and mast cells (Johnson et al., 
1975, Venkatesha et al., 2005) undergo degranulation and release histamine upon C3a-C3aR 
interaction. C3aR stimulates production of ECP from eosinophils (Takafuji et al., 1994), as 
well as upregulation of ǃ2-integrins and shedding of L-selectins, thereby promoting 
eosinophil adhesion to endothelial and epithelial cells (Jagels et al., 2000).  Human 
monocytes and mast cells exhibit increased intracellular calcium (Ca2+) levels when 
stimulated with C3a (Venkatesha et al., 2005). C3a also stimulates smooth muscle 
contraction (Stimler et al., 1983), lysozyme release from immune cells (Showell et al., 1982), 
platelet aggregation (Becker et al., 1978), and triglyceride synthesis in adipocytes (Baldo et 
al., 1993).  
3.1.4 Signaling 
Upon C3a binding to the C3aR, intracellular signal transduction is promoted via 
heterotrimeric guanosine triphosphate (GTP)-binding proteins (G proteins).  C3aR mediates 
its effect on immune cells via coupling to the pertussis toxin (PTX)-sensitive and –insensitive 
G proteins Gǂi and Gǂ16, respectively. In endothelial cells, C3aR also couples to PTX-
insensitive Gǂ12 and Gǂ13 (Schraufstatter et al., 2002). Downstream signaling events involve 
activation of phosphoinositol-3-kinase gamma (PI3K-Ǆ), which in turn activates 
phospholipase C (PLC)ǃ and PLCǄ. This leads to generation of inositol triphosphate (IP3) 
and diacylglycerol (DAG), leading to Ca2+ mobilization and phosphokinase C (PKC) 
activation, respectively. PI3K can also activate Raf/mitogen-activated protein kinase 
(MAPK)/extracellular-signal regulated kinase (ERK) kinase (MEK)/ERK cascade inducing 
expression of various pro-inflammatory cytokines and chemokines.  
3.2 C5a receptor (C5aR or CD88) 
First cloned in 1991 (Boulay et al., 1991, Gerard and Gerard, 1991), C5aR is a membrane 
glycoprotein of approximately 42 kDa (Richardson et al., 1998), displaying high affinity for 
C5a and C5a desArg. Human C5aR binds C5a with a Kd of 1 nM, and with 10 to 100-fold 
lower affinity to C5a desArg (Kd of 412-660 nM) whereas C3a and C3a desArg are not 
recognized (Monk et al., 2007). 
3.2.1 Structure 
Similar to C3aR, C5aR is a seven transmembrane GPCR that belongs to the rhodopsin-like 
family. Based on the analysis of transmembrane domain sequences, C5aR is clustered with 
other chemoattractant receptors, such as C3aR, formyl peptide receptor family, ChemR23, 
platelet activating factor (PAF) receptor, IL-8 receptor, and bradykinin receptor (Methner et 
al., 1997, Samson et al., 1998). The C5aR gene is localized to q13.3-13.4 of human 
chromosome 19 (Gerard et al., 1998). Murine C5aR exhibits 65% sequence identity with its 
human counterpart (Gerard et al., 1992). The N terminus of C5aR is required for high 
affinity binding of C5a, but not for receptor activation (DeMartino et al., 1994, Mery and 
Boulay, 1993). A second distinct binding site is formed by charged residues in the second 
and third extracellular loops and the external faces of the transmembrane helical bundle and 
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hydrophobic residues in the core of the C5aR. Unlike the N terminal binding site, the second 
site is responsible for receptor activation (Gerber et al., 2001). Current evidence suggests that 
at least three different discontinuous regions exist within the C5a molecule for interaction 
with C5aR (Huber-Lang et al., 2003). 
3.2.2 Expression 
C5aR is expressed on cells of myeloid origin such as neutrophils, eosinophils, basophils, 
mast cells, dendritic cells and monocytes, as well as on non-myeloid cells, including 
bronchial and alveolar epithelial cells, endothelial cells, Kupffer cells, stellate cells, 
astrocytes and microglial cells (Monk et al., 2007).  
3.2.3 Biological role 
C5aR is a powerful chemoattractant receptor for monocytes (Pieters et al., 1995), neutrophils 
(Webster et al., 1980), eosinophils (DiScipio et al., 1999), basophils (Lett-Brown and Leonard, 
1977), mast cells (Hartmann et al., 1997), B cells (Kupp et al., 1991) and T cells (Nataf et al., 
1999). It also stimulates mast cell degranulation (Subramanian et al., 2011), mast cell 
chemotaxis in specific mast cell subtypes (Hartmann et al., 1997, McCloskey et al., 1999), 
oxidative burst in granulocytes and the production of reactive oxygen species (ROS) in 
neutrophils (Guo et al., 2003), secretion of lysosomal enzymes from macrophages (McCarthy 
and Henson, 1979) and polymorphonuclear (PMN) cells as well as the secretion of pro-
inflammatory mediators from monocytes, eosinophils (Takafuji et al., 1994) and mast cells 
(Hartmann et al., 1997). C5a is also responsible for upregulation of vascular adhesion 
molecules such as E-selectin, inter-cellular adhesion molecule 1 (ICAM-1) and vascular cell 
adhesion molecule 1 (VCAM-1) after systemic activation of complement (Albrecht et al., 
2004, Jagels et al., 2000). Our preliminary findings suggest that C5a can promote human 
mast cell adhesion to extracellular matrix protein, as well as human mast cell migration in 
vitro, indicating a critical role of C5a/C5aR in inflammation.   
3.2.4 Signaling 
C5aR signaling depends on heterotrimeric G proteins. C5aR mainly couples to Gǂi2, a PTX-
sensitive G protein (Skokowa et al., 2005). However, ectopically expressed C5aR, and C5aR 
on cells of the hematopoietic lineage, can also couple to PTX-insensitive Gǂ16 (Amatruda et 
al., 1993, Monk and Partridge, 1993). C5a-C5aR interaction leads to activation of several 
components of signaling pathway, including PI3K-Ǆ, PLCǃ2, and phospholipase D (PLD) 
(Rabiet et al., 2007). C5aR can activate the transcription factor, cyclic AMP (cAMP) response 
element-binding protein (CREB), by phosphorylation at the convergence of two pathways, 
PI3K/Akt and ERK (Perianayagam et al., 2006). CREB activation has been proposed to be a 
part of the mechanism by which C5a can delay neutrophil apoptosis and prolong an 
inflammatory response (Perianayagam et al., 2004). In neutrophils, C5a causes downstream 
activation of p21-activated kinases (PAK), which are downstream effectors of cdc42 and rac 
(small guanosine triphosphate (GTP)-binding proteins (GTPases)), as well as GǄ subunits 
(Huang et al., 1998). PAK family members are involved in altering cell 
morphology/chemotaxis, activation or potentiation of several distinct MAPK cascades and 
the activation of nuclear factor (NF)-kB in macrophages. p38 MAPK is activated by 
PAK1/PAK2 and, in turn, activates MAPK-activated protein kinase 2 (MAPKAP-K2). In 
primary macrophages from MAPKAP-K2-deficient mice, chemotaxis to C5a is impaired. 
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Furthermore, the p38 MAPK inhibitor, SB203580, can inhibit C5a-induced migration in a 
mouse acute lung injury model (Rousseau et al., 2006).  
C5aR also couples directly or indirectly to a small range of other intracellular proteins. The 
Wiskot–Aldrich syndrome protein (WASP) was detected as a binding partner of the C- 
terminus of C5aR using a yeast two-hybrid assay. WASP binding was strongly potentiated 
in the presence of active cdc42, suggesting that the association occurs after C5aR activation 
(Tardif et al., 2003). WASP is a multifunctional protein with a role in the regulation of actin 
dynamics, and so could be involved in the chemotactic response to C5a. In human 
erythroleukaemia cells, signal transducers and activators of transcription (STAT3) 
phosphorylation can be stimulated by C5a in a PTX-insensitive manner, most likely through 
Gǂ16 and the Ras/Raf/MEK/ERK and janus kinase (JAK) pathways (Lo et al., 2006). In 
contrast, STAT3 phosphorylation occurs only through an ERK pathway in C5a-stimulated 
neutrophils (Kuroki and O'Flaherty, 1999).  
3.3 C5a receptor-like 2 (C5L2) 
First discovered in 2000 as a putative orphan receptor (GPR77), (Ohno et al., 2000) C5L2 has 
since been identified as a second C5a receptor. It is a 37 kDa protein and binds C5a with 
high affinity (Kd of 2.5 nM). Unlike C5aR, C5L2 binds C5a desArg with a 20-30 fold higher 
affinity (Cain and Monk, 2002).  
3.3.1 Structure 
C5L2 consists of 337 amino acids with asparagine 3 as a potential glycosylation site (Ohno et 
al., 2000). In the conserved transmembrane regions, C5L2 shares 58% sequence identity with 
C5aR and 55% with C3aR (Lee et al., 2001). Unlike C5aR, C5L2 uses critical residues in its N 
terminal domain for binding only to C5a desArg. In addition to C5a and C5a desArg 
binding, C5L2 has been considered a binding partner for C3a, C3a desArg (Kalant et al., 
2005), C4a and C4a desArg; however the available data is not very convincing (Johswich et 
al., 2006, Okinaga et al., 2003).  
Although C5L2 has the conventional structure of a GPCR, studies have found that C5L2 
does not couple to G proteins. This may be due to a structural difference in the third 
transmembrane domain. In GPCR, a highly conserved DRY motif in the third 
transmembrane domain is important for its interaction with the corresponding G proteins. 
The DRY motif is DRC in C3aR and DRF in C5aR, but DLC in C5L2. Moreover, the third 
transmembrane domain of C5L2 is truncated. Mutation of DLC in human C5L2 to DRC has 
been shown to increase coupling to Gǂ16 in co-transfected human embryonic kidney 
(HEK)293 cells and induce a functional response (Okinaga et al., 2003). Interestingly, no 
functional response occurs in rat basophilic leukemia cells (RBL-2H3) using a C5L2-
mutant where the DRY-motif and two additional regions typically involved in G protein 
coupling are replaced by the corresponding C5aR sequences (Scola et al., 2009). Taken 
together, these findings strongly suggest that C5L2 completely lacks the potential to 
couple with G proteins. 
3.3.2 Expression 
C5L2 is expressed in various tissues of myeloid and non-myeloid origin and transcripts are 
detected in brain, placenta, ovary, testis, spleen and colon. Surface expression of C5L2 has 
been detected in lung, liver, heart, kidney, adipose tissue, skin fibroblasts, neutrophils, and 
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immature, but not mature dendritic cells. In the presence of a C5aR antagonist, binding of 
C5a has been demonstrated on differentiated myeloblastic HL-60, U937, and epithelial 
HeLa-cells. C5L2 and C5aR seem to be frequently co-expressed in most cells or tissues 
(Monk et al., 2007). 
3.3.3 Biological role and signaling 
C5L2 is an enigmatic receptor as available data suggest opposing roles. On the one hand, 
C5L2 has been described as a non-signaling decoy receptor for C5a and C5a desArg. In 
contrast, some studies suggest that C5L2 serves as a signaling functional receptor. In 
support of a role as a decoy receptor, no mobilization of intracellular Ca2+ occurs in C5L2 
transfected cells after C5a administration (Cain and Monk, 2002, Okinaga et al., 2003). 
Moreover, no Ca2+ mobilization occurs in neutrophils from C5aR-deficient mice after 
stimulation with C5a (Hopken et al., 1996) or in C5L2 expressing epithelial and myeloid cell 
lines (Johswich et al., 2006). In the presence of C5a and C5a desArg, C5L2 transfected RBL-
2H3 cells do not degranulate (Cain and Monk, 2002). Further, C5a binding to C5L2 in bone 
marrow cells derived from C5aR-deficient mice fails to induce any changes in messenger 
RNA (mRNA) expression (Okinaga et al., 2003).  
Nevertheless, there is accumulating evidence that C5L2 is a functional receptor capable of 
regulating C5aR function in vitro and in vivo. Neutrophils and macrophages from C5L2-
deficient mice produce more tumor necrosis factor (TNF)ǂ and interleukin (IL)6 in response 
to stimulation with C5a and lipopolysaccharide (LPS) than their wildtype (WT) 
counterparts. Further, C5a+LPS stimulation drive more IL-6 production from rat neutrophils 
when C5L2 is blocked (Gao et al., 2005). In vivo, C5L2-deficient mice suffer from augmented 
inflammatory responses and higher numbers of infiltrating neutrophils in a model of 
pulmonary immune complex injury (Gerard et al., 2005), indicating an anti-inflammatory 
function of C5L2. The anti-inflammatory role of C5L2 is further supported by a study in 
which LPS-injected C5L2-deficient mice show higher IL-1ǃ levels and decreased survival 
rates (Chen et al., 2007). Similarly, C5L2-deficient mice display higher serum concentrations 
of IL-6 as compared to WT and C5aR-deficient mice in a model of septic peritonitis (Rittirsch 
et al., 2008). 
In contrast, under the same conditions, a strong reduction of other inflammatory mediators, 
such as IL-1ǃ, macrophage inflammatory protein (MIP)-1ǂ and MIP-2 is observed in C5L2-
deficient mice compared to WT mice. Indeed, the plasma concentrations of these mediators 
are comparable to those found in C5aR-deficient mice. Furthermore, C5L2-deficient mice, 
like C5aR-deficient mice, or mice in which either of the receptors are blocked by anti-
receptor antibodies, show a higher survival rate in mid-grade sepsis (Rittirsch et al., 2008). 
Contrasting the in vitro findings that C5a+LPS-driven IL-6 production by mouse neutrophils 
is increased when C5L2 is blocked by antibodies (see above), Chen et al. found that IL-6 
release is reduced from C5L2-deficient neutrophils (Chen et al., 2007). Moreover, C5a+LPS-
induced Mac-1 surface expression on these neutrophils also diminishes, suggesting 
neutrophils chemotaxis may be impacted. Likewise, whereas C5a or C5a+LPS stimulation 
can lead to strong ERK1/2- and AKT-phosphorylation in neutrophils from WT mice, there is 
only a weak effect in the absence of C5L2. Additionally, C5L2-deficient macrophages have 
an impaired induction of co-stimulatory molecules (CD40, CD86). Even C3a mediated 
effects such as ERK1/2- and Akt-phosphorylation or F-actin formation on neutrophils are 
impaired in C5L2-deficient mice (Chen et al., 2007). In addition to these in vitro findings, 
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inflammatory responses are reduced in vivo in models of thioglycollate induced peritonitis, 
thioglycollate induced migration into dorsal air pouches, and ovalbumin (OVA) induced 
airway hyperresponsiveness (AHR) (Chen et al., 2007). Thus, these studies point to a more 
complex role of C5L2 in inflammation with C5L2 acting not only as a decoy receptor but 
also as positive modulator of C5aR and even C3aR. Although C3a desArg does not bind 
directly to C5L2, overexpression of C5L2 or its downregulation by antisense 
oligonucleotides influences the effects of C3a desArg (Kalant et al., 2005), suggesting that 
C5L2 can modulate signaling pathways of other receptors.  
Although C5L2 does not appear to signal using the traditional mechanisms employed by 
GPCRs, several studies suggest that C5L2 has the ability to induce cellular effects. A recent 
study has found that noradrenaline upregulates C5L2 message and protein in rat astrocytes, 
and this correlates with an anti-inflammatory response induced by noradrenaline. 
Transfection of astrocytes by C5L2 down regulates NF-kB activity, whereas antisense 
oligonucleotides against C5L2 induce the reverse effect (Gavrilyuk et al., 2005). These 
observations suggest that the presence of C5L2 may exert some inhibitory effects within the 
cell, although the mechanisms behind such responses are currently unknown.  
4. Regulation of complement receptor signaling 
GPCR represent the largest family of cell surface receptors in the human genome, allowing 
extracellular signals to regulate a vast number of physiological events. Following ligand 
binding, GPCR undergo a conformational change which activates heterotrimeric G proteins. 
G proteins exist as a complex of Gǂ and GǃǄ subunits. Upon activation, GDP is displaced by 
GTP from the Gǂ subunit resulting in disassociation of Gǂ subunit from the GǃǄ subunits. 
This facilitates the free subunits interactions with various effector molecules and initiates 
downstream signaling (Pundir and Kulka, 2010). In the immune system, GPCRs play a role 
in innate, adaptive and pathological responses. In allergic diseases, stimulation of the 
GPCRs, C3aR and C5aR, by C3a and C5a, respectively produces a diverse array of effector 
functions, ranging from inflammatory cell migration to pro-inflammatory mediator 
production, thus contributing towards the pathophysiology of the diseases.  
Given that the activation of C3aR and C5aR can induce massive inflammation and tissue 
destruction, there are mechanisms in place to limit complement activation where and when 
it occurs. As mentioned before, after generation, C3a and C5a are quickly degraded by 
plasma carboxypeptidases. The enzyme cleave the C-terminal arginine, resulting in C3a 
desArg and C5a desArg formation, each having less than 10% of their original biological 
activity (Bokisch and Muller-Eberhard, 1970). Formation of C3a and C5a is also regulated by 
either preventing the assembly of C3 convertase or, once it is formed, by inhibiting its 
activity. This is accomplished through the actions of decay acceleration factor (DAF), C4 
binding protein (C4BP) and Factor H (Sarma and Ward, 2011). In addition, desensitization to 
prolonged or repeated exposure to high agonist concentration is another important 
mechanism of GPCR regulation. Furthermore, G proteins may terminate their own 
activation by Gǂ hydrolysis of GTP, thereby allowing Gǂ-GDP to reunite with GǃǄ and 
form an inactive heterotrimer (Tsang et al., 1998). As this reaction proceeds at a slow rate 
(Tsang et al., 1998), additional cofactors come into play that aid in GPCR desensitization. 
Indeed, there are around 30 isoforms of Regulator of G protein signaling (RGS) proteins, 
which bind to activated Gǂ subunit and accelerate their intrinsic GTPase activity (Willars, 
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2006). RGS13 can regulate human mast cell lines, HMC-1 and laboratory of allergic diseases 
(LAD)2, response to C5a. RGS13-deficient HMC-1 cells have more cytosolic Ca2+ in response 
to C5a, indicating that RGS13 regulates C5aR-stimulated events in immune cells (Bansal et 
al., 2008).  
GPCR desensitization is also achieved by the G protein-coupled receptor kinase (GRK)-
arrestin pathway. There are seven GRKs in humans, GRK1-7, and four arrestins, arrestin 1-4. 
Most GPCRs are regulated by only four GRKs: GRKs 2, 3, 5, or 6, and two arrestins: arrestin-
2 (ǃ-arrestin1) and arrestin-3 (ǃ-arrestin2) (Premont and Gainetdinov, 2007). Agonist-
induced desensitization of GPCRs occurs via a multistep process. Just as G proteins 
recognize activated GPCR, GRKs also recognize activated GPCR, which leads to receptor 
phosphorylation at various serine/threonine residues on the intracellular loops and the 
carboxyl-terminal tail (Langkabel et al., 1999). Upon phosphorylation by GRK, GPCR’s 
affinity for arrestin proteins is increased, which prevents the receptor from activating 
additional G proteins. The ǃ-arrestins interact with clathrin and the adaptor protein 
complex AP-2 and target the agonist occupied receptors to pre-existing clathrin-coated 
pits for internalization. Thus GRK phosphorylation and arrestin binding result in 
termination of GPCR signaling, despite the continued presence of agonist (Santini et al., 
2002, Scott et al., 2002).  
A study by Ahamed et al. has shown that C3a stimulates degranulation and chemokine 
monocyte chemotactic protein-1 (MCP-1) production in RBL-2H3 cells expressing C3aR. 
Stimulation with C3a causes phosphorylation of WT C3aR but not of phosphorylation- 
deficient C3aR (ΔST-C3aR). In addition, C3a stimulation increases degranulation only in 
RBL-2H3 cells expressing ΔST-C3aR, suggesting that receptor phosphorylation provides an 
“off” signal for degranulation. Overexpression of GRK2 in C3aR-transfected cells results in 
increased C3a-induced C3aR phosphorylation. This increase in receptor phosphorylation is 
associated with a significant inhibition of degranulation. Furthermore, C3a causes a rapid 
translocation of ǃ-arrestin2 from the cytosol to the membrane in RBL-2H3 cells expressing 
C3aR but not in cells expressing ΔST-C3aR, indicating that GRK2-induced C3aR 
phosphorylation is required for ǃ-arrestin recruitment following C3a stimulation (Ahamed 
et al., 2001). Similarly, in transfected COS cells, overexpression of GRK2, GRK3, GRK5 or 
GRK6 results in enhanced C3a-induced C3aR phosphorylation (Langkabel et al., 1999). 
Knockdown of GRK2 or GRK3 expression in HMC-1 and LAD2 cells, causes higher Ca2+ 
mobilization, attenuated C3aR desensitization, and enhanced degranulation, thus indicating 
GRK2 and GRK3 involvement in C3aR desensitization. On the other hand, GRK5 or GRK6 
knockdown in HMC-1 and LAD2 cells has no effect on C3aR desensitization, but instead 
promotes C3a-mediated degranulation, suggesting a complex role for GRKs in regulating 
human mast cells (Guo et al., 2011).  
A recent study has identified the roles of ǃ-arrestin1 and ǃ-arrestin2 on C3aR desensitization 
and internalization (Vibhuti et al., 2011). By stably knocking down their expression in HMC-
1 cells, this study shows that ǃ-arrestin2, but not ǃ-arrestin1, is required for C3aR 
desensitization and internalization. Interestingly, ǃ-arrestin1-deficient, but not ǃ-arrestin2-
deficient, HMC-1 cells show reduced NF-κB activation and chemokine MIP-1ǃ generation in 
response to C3a. Similar knock-down study with LAD2 cells shows that the absence of ǃ-
arrestin1, but not ǃ-arrestin2, significantly inhibits C3a-induced degranulation. This 
demonstrates that ǃ-arrestin1 and ǃ-arrestin2 play a distinct role on C3aR desensitization, 
internalization and mediator generation in human mast cells (Vibhuti et al., 2011).  
www.intechopen.com
 
Complement Receptors in Inflammation 
 
171 
Upon ligand binding, C5aR undergoes rapid phosphorylation of the six serine residues 
located in the carboxyl-terminal tail (Giannini et al., 1995). This phosphorylation is a critical 
step in the termination of the C5aR signaling since a phosphorylation-deficient C5aR mutant 
triggers sustained intracellular signaling leading to increased C5a-induced superoxide 
production by HL-60 cells (Christophe et al., 2000). A study by Braun et al. shows that a 
persistent complex between activated/phosphorylated C5aR and ǃ-arrestins is necessary for 
receptor desensitization and internalization. WT C5aR and ǃ-arrestin1-transfected RINm5F 
cells exhibit significant ǃ-arrestin1 recruitment to the plasma membrane when stimulated 
with C5a. Moreover, in resting RINm5F cells, the C5aR is mainly located in the plasma 
membrane, and both ǃ-arrestin1 and ǃ-arrestin2 are evenly distributed throughout the 
cytoplasm. Upon addition of C5a, ǃ-arrestin1 and ǃ-arrestin2 rapidly move from the cytosol 
to the plasma membrane, co-localize with C5aR, promote endocytosis of C5aR and remain 
associated to C5aR-containing vesicles. Furthermore, this study also indicates that C5aR is 
mainly internalized via the classical clathrin-dependent pathway (Braun et al., 2003). 
Interestingly, an observation by Bamberg et al. reveals that in resting neutrophils C5L2 is 
distributed throughout the cytoplasm co-localized with ǃ-arrestin, while C5aR is expressed 
on their surface. Following stimulation with C5a, association of both C5aR and C5L2 with ǃ- 
arrestin is greatly increased. Cells treated with an anti-C5aR antibody when activated with 
C5a fail to translocate C5L2 to ǃ-arrestin, indicating that the activation of C5L2 is a 
consequence of C5aR activation. Moreover, C5L2-ǃ-arrestin complex is a negative regulator 
of C5aR signaling in neutrophils (Bamberg et al., 2010).  
Thus, a number of mechanisms have evolved to efficiently regulate complement activation; 
however, these regulatory mechanisms seem to fail in various clinical and experimental 
situations underlining the important role of complement proteins and their complement 
receptors in the pathogenesis of inflammatory diseases. These include airway inflammation 
and asthma (Wagner et al., 1999), sepsis (Gao et al., 2005), multiple organ dysfunction 
(Mastellos et al., 2005), hyperactute graft rejection (Link et al., 1999), ischemic injuries of 
various organs (Arumugam et al., 2004), autoimmune disorders such SLE (Karp, 2005) or 
multiple sclerosis (Rus et al., 2005), neurological diseases such as stroke (Yanamadala and 
Friedlander), and cancer (Yan et al., 2008).  
5. Diseases associated with complement function 
5.1 Allergic inflammation: Allergic asthma 
Asthma is a chronic inflammatory disorder of the airways characterized by variable airflow 
obstruction, and associated increase in airway responsiveness to a variety of stimuli. The 
clinical features of asthma include dyspnea, wheezing and coughing. It is thought to be 
mediated primarily by allergen-specific CD4+ T cells, T helper (Th)2 cytokines, and allergen-
specific IgE, leading to pulmonary inflammation and AHR. Complement is well recognized 
as an important factor in the pathophysiology of asthma.  
In allergic asthma and allergic rhinitis conditions, the complement system is activated by 
several pathways leading to the cleavage of C3 and/or C5 into their active fragments. First, 
the presence of preexisting allergen-specific antibodies in asthmatic patients can activate the 
classical pathway through formation of immune complexes. Second, the alternative 
pathway can be initiated by nucleophilic attack of C3 directly on the surface of allergen or 
by Factor B (Taube et al., 2006). Third, the recognition of PAMPs and danger-associated 
molecular patterns (DAMPs), such as nucleic acids on apoptotic cells (Elward et al., 2005) or 
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allergen polysaccharide, (Bito, 1977, Zimmermann et al., 1989) can activate the lectin 
pathway. Fourth, proteases released from inflammatory cells (Huber-Lang et al., 2002) or 
direct protease activity of allergens (Maruo et al., 1997) can drive the generation of C3a and 
C5a. Indeed, a variety of allergens have been shown to activate the complement and 
generate C3a and C5a in the airways. Ragweed extracts activate the complement cascade in 
both allergic individuals and healthy controls; however, generation of C3a is much stronger 
in allergic patients (Gonczi et al., 1997, Hidvegi et al., 1995). Ragweed allergen challenge also 
promotes C3a generation in the nasal mucosa of patients with allergic rhinitis. House dust 
mite (HDM), Aspergillus fumigatus and perennial ryegrass extracts induce serum C3a and 
C5a production in a dose and time-dependent manner (Nagata and Glovsky, 1987). 
Proteases from Dermatophagoides spp. (in particular, Der p 3 and Der f 3) can cleave C3 and 
C5 into their active fragments (Castro et al., 1991, Maruo et al., 1997). During an ongoing 
allergic reaction the Th2 cytokine IL-4 induces C3 mRNA production in human and murine 
epithelial cells (Khirwadkar et al., 1993).  
Collectively, these studies provide strong evidence that major complement activation, and 
C3a and C5a generation occurs in asthmatic individuals. C3a and C5a are important 
contributing factors in the pathophysiology of asthma, because of their ability to recruit and 
activate inflammatory immune cells such as mast cells, eosinophils, macrophages, 
neutrophils, and basophils, increase vascular permeability, stimulate smooth muscle 
contraction, and trigger mast cell degranulation (Wust et al., 2006). Several studies have 
reported marked anaphylatoxins production under asthmatic condition. In the serum of 
asthmatic patients, an increase in C3a and C5a levels have been observed after allergen-
induced bronchospasm (Arroyave et al., 1977, Smith et al., 1990). The levels of C3a, and to a 
lesser extent C5a increase in the bronchoalveolar lavage fluid (BALF) of asthmatic patients 
after segmental allergen provocation. Similarly, allergen-challenged lung lobes show 
significantly higher C3a levels in comparison to diluent (sham)-challenged lobes from 
asthmatic individuals (Humbles et al., 2000). In addition, sputum from patients with 
asthma exhibit increased C5a/C5a desArg concentrations (Marc et al., 2004). Infact, 
plasma C5a desArg levels reflect allergic disease severity (Bowser et al., 2010). 
Complement C3a and C4a concentrations increase in plasma of patients with aspirin-
induced asthma (Lee et al., 2006). Studies with animal models of AHR have also indicated 
that C3a and C5a are crucial for asthma pathogenesis (Abe et al., 2001, Bautsch et al., 2000, 
Drouin et al., 2002, Lukacs et al., 2001).  
In addition to allergen-mediated mechanisms, environmental stimuli can also trigger 
complement activation. Airborne pollutants such as diesel exhaust particles or airborne 
particulate matter can activate complement through the alternative pathway in human 
serum and airway epithelium, respectively (Walters et al., 2002). Moreover, acute ozone 
exposure can induce AHR and neutrophil infiltration, accompanied by elevated C3 levels in 
BALF in mice (Lambrecht and Hammad, 2009, Park et al., 2004). Cigarette smoke has been 
shown to directly activate the alternative pathway through cleavage of the internal thioester 
bond in C3 (Kew et al., 1987). Consistent with these studies, elevated levels of C3 have been 
found in children from smoking homes compared to those from non-smoking homes (Shima 
and Adachi, 1996).  
Candidate gene and genome-wide screens for asthma susceptibility loci have identified C5 
(9q34) (Ober et al., 1998, Wjst et al., 1999) and C5aR (19q.13.3) gene-containing chromosomal 
regions to be linked to asthma susceptibility (CSGA, 1997, Ober et al., 1998). One study 
reports an association between a single nucleotide polymorphism (SNP) in the C3 gene and 
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atopic asthma in children and adults in a Japanese population. On the other hand, SNPs in 
the human C5 gene are associated with protection against both childhood and adult asthma. 
The authors also report a significant association between a SNP in the C3a receptor (C3ar1) 
gene and childhood asthma (Hasegawa et al., 2004). These observations may explain the 
opposing role of C3 and C5 in animal-based asthma studies. C3-deficient mice when 
challenged with an allergen to induce pulmonary allergy exhibit diminished AHR and lung 
eosinophilia. Furthermore, these mice show markedly reduced IL-4 secreting cells and 
attenuated allergen-specific IgE response (Drouin et al., 2002). Collectively, these results 
demonstrate that C3 promotes Th2 effector function in asthma. On the other hand, the A/J 
mouse strain in which allergic inflammation and AHR can be easily induced, are deficient in 
C5 (Karp et al., 2000), demonstrating that C5-deficient mice are more susceptible to 
experimental asthma. Furthermore, in vitro experiments have shown that peritoneal 
macrophages from C5-deifcient A/J mice produce significantly less IL-12, because IL-12 is 
critical for promotion of Th1 immune response (Karp et al., 2000), these studies suggest that 
dysfunction in C5 cleavage may influence susceptibility to asthma. In contrast, a study by 
Peng et al. has demonstrated the contribution of C5 in the development of airway 
inflammation, AHR and ongoing allergic response in OVA-sensitized mice (Peng et al., 
2005). Pharmacological inhibition of C5 using a monoclonal antibody against C5, BB5.1, 
markedly attenuates airway obstruction, perivascular and peribronchial infiltration of 
inflammatory cells, and BALF levels of inflammatory mediators such as eotaxin, regulated 
upon activation, normal T-cell expressed and secreted (RANTES), TNFǂ, and matrix 
metalloproteinase (MMP)9 (Peng et al., 2005).  
The paradoxical effects of C5 and C5a observed in allergic asthma may be due to C5 
behaving differently during allergen sensitization as opposed to during established allergic 
inflammation. Evidence to this effect was provided by Kohl et. al in a study utilizing two 
models of pulmonary asthma: a) OVA sensitization and challenge of mice leading to 
inhalation tolerance; and b) HDM sensitization and challenge of mice which induce Th2 
sensitization, airway inflammation, and AHR. Ablation of C5aR signaling by 
pharmacological targeting prior to initial pulmonary OVA challenge, using a neutralizing 
anti-C5aR monoclonal antibody, induces significant production of Th2 cytokines (IL-5, IL-
13, and IL-10), high serum IgE levels, marked influx of inflammatory cells (eosinophils, 
neutrophils, and lymphocytes) into BALF, mucus production, and AHR. Similar results are 
observed when C5aR is blocked prior to initial pulmonary HDM challenge. Together, this 
data suggests that the presence of C5a in the airways at the time of initial allergen encounter 
serves to prevent the development of Th2-mediated immune response (Kohl et al., 2006).  
Protection against allergic sensitization by C5aR activation is a complex process involving 
alterations in the function of APCs, in particular dendritic cells. Dendritic cells strategically 
located in the upper layers of the epithelium and lamina propria of the airways, are 
specialized for the recognition and internalization of PAMPs. Once loaded with allergen, 
dendritic cells migrate to draining lymph nodes and present antigen to naïve T cells, which 
under appropriate polarizing cytokine signals, differentiate into effector T cells (Banchereau 
and Steinman, 1998). Dendritic cells are composed of several subsets, some of which drive 
the development of an aberrant adaptive immune response. The two dendritic cell subsets 
which have been found in the bronchial airways are myeloid dendritic cells (mDCs) and 
plasmacytoid dendritic cells (pDCs) (GeurtsvanKessel and Lambrecht, 2008). Pulmonary 
mDCs function as the major APCs in mouse models of allergic asthma, preferentially 
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inducing Th2 immune response towards inhaled allergen (Lambrecht et al., 2000). 
Pulmonary pDCs are immature dendritic cells, which induce respiratory tolerance by 
directly suppressing mDC-mediated activation of CD4+ T effector cells or by inducing 
regulatory T cells (Tregs, a heterogeneous population of T cells that can suppress allergic 
immune responses) (GeurtsvanKessel and Lambrecht, 2008).  
Several studies suggest that the ratio between mDCs and pDCs is critical for the 
development of the dysregulated Th cell response and that C5a regulates this ratio, thereby 
modulating the development of the allergic phenotype during allergen sensitization. CD4+ T 
cells from mice challenged with HDM allergen in presence of an anti-C5aR monoclonal 
antibody produce higher levels of Th2 cytokines in co-culture with mDCs, but not with 
pDCs. Importantly, in the same setting, pDCs suppress the mDC-induced production of Th2 
cytokines (Kohl et al., 2006). Furthermore, exposure to HDM leads to an increased number 
of mDCs, whereas the number of pDCs remains unaffected. These findings demonstrate that 
C5aR signaling controls the accumulation of pulmonary mDCs and pDCs in lungs, keeping 
the mDC:pDC ratio low, which facilitates the suppressive effects of pDCs on the mDC-
mediated activation of T cells. In addition, C5aR blockade positively regulates the 
production of thymus and activation regulated chemokine (TARC) and macrophage-
derived chemokine (MDC), thus promoting the recruitment of Th2 effector cells into the 
lungs (Kohl et al., 2006). Data obtained from C5-deficient mice indicate that C5aR signaling 
is required to keep mDC susceptible to suppression Tregs, thereby controlling the 
immunogenic effect of mDC (Lewkowich et al., 2005).  
A study by Zhang et al. demonstrates that regulation of co-stimulatory molecules on mDCs 
and pDCs is an important mechanism underlying the protective impact of C5aR signaling 
on the development of the Th2 immune response. HDM exposure increases the frequency of 
pulmonary mDCs expressing B7-H1 and B7-DC. In vivo ablation of C5aR signaling 
dramatically reduces the frequency of pDCs expressing B7-H1 and B7-DC. In the presence of 
C5aR signaling, blockade of B7-H1 or B7-DC results in enhanced Th2 cytokine production 
by T cells, suggesting that B7-H1 and B7-DC are critical for pDC-driven regulation of mDCs, 
and protection against allergic sensitization (Zhang et al., 2009). Interestingly, C5aR 
expression on dendritic cells might be downregulated in the Th2 cytokine-dominated 
environment, thus dampening the negative regulatory effect of C5aR signaling, in particular 
on pDCs. Indeed, high levels of IL-4 downregulates C5aR expression in monocyte-derived 
dendritic cells (Soruri et al., 2003). 
In the absence of C5aR, C5a binds C5L2, which has a similar distribution in lung tissue as 
C5aR. The pro-allergic role of C5L2 in experimental asthma has been demonstrated recently. 
OVA-sensitized C5L2-deficient mice exhibit reduced AHR, inflammatory cell infiltration, 
and airway inflammation (Chen et al., 2007). Similarly, HDM-sensitized C5L2-deficient mice 
show significantly attenuated AHR and airway inflammation that is associated with 
decreased mucus production, Th2 cytokine production, and serum IgE levels (Zhang et al., 
2010), confirming the pro-inflammatory role of C5L2 in the development of asthma. The 
available data further indicates that C5L2 also has a regulatory impact on mDCs. Adoptive 
transfer of C5L2-deficient mDCs into WT mice results in decreased eosinophilic and 
lymphocytic inflammation and a decreased IgE response. Importantly, C5L2-deficient mDCs 
still promote production of large amounts of Th2 cytokines from lung cells; however, in 
contrast to their WT counterparts, the production of Th1 and Th17 cytokines is also 
enhanced, and is associated with an increased neutrophil influx. Moreover, HDM 
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stimulation of C5L2-deficient mDCs results in production of the Th17-promoting cytokine 
IL-23. Collectively, this suggests a complex role of C5L2 in asthma; controlling the 
development of Th1 and Th17 cells in response to allergen challenge as well as driving the 
Th2 immune response (Zhang et al., 2010).  
Th17 are IL-17A–producing subset of CD4+ T cells which have received much interest 
recently in allergy research. Several reports suggest that in addition to Th2 cells, Th17 cells 
contribute to the development of allergic inflammation. Sputum IL-17A mRNA is 
significantly elevated in asthmatic patients, and correlates with increase in sputum 
neutrophil counts (Bullens et al., 2006). Bronchial biopsies taken from patients with severe 
asthma show massive infiltration of IL-17 producing Th17 cells (Pene et al., 2008). In 
experimental asthma, IL-17A (Hellings et al., 2003) and Th17 (McKinley et al., 2008) cells 
have been shown to promote bronchial influx of neutrophils and induce airway 
inflammation and AHR. Th17 cells not only mediate neutrophilic airway inflammation, they 
also upregulate airway eosinophilia, together with IL-23 (Wakashin et al., 2008). Recent 
studies have highlighted an important dual role for C5a in Th17 cell development. C5aR-
deficient mDCs show elevated production of Th17 promoting cytokines (transforming 
growth factor (TGF)-ǃ, IL-6, and IL-23) and Th17 cell differentiation (Weaver et al., 2010). 
Furthermore, A/J mice (lacking C5) develop severe AHR associated with elevated levels of 
IL-17A and Th2 cytokines in comparison to C3H/HeJ strain of mice (mice manifesting less 
severe AHR). HDM challenge induces increased frequency of Th17 cells, as well as IL-17A in 
lungs of A/J mice. In vivo blockade of IL-17A with an anti-IL-17A antibody reduces AHR 
and BALF neutrophilia in HDM challenged A/J mice. Furthermore, an inverse relationship 
is found between the serum C5a concentration and the frequency of Th17 cells and IL-17A 
staining in lungs of HDM challenged A/J mice. Pharmacological inhibition of C5aR in 
BALB/c mice leads to enhanced influx of Th17 cells into the lungs after HDM challenge, and 
increased production of IL-17A per cell. Also, dendritic cells from these mice produce more 
HDM-driven IL-23. Taken together this suggests that C5a/C5aR complex controls IL-17A by 
limiting IL-23 production (Lajoie et al., 2010). As described above, Th17 development in 
experimental asthma is not only regulated by C5aR but by C5L2 as well (Zhang et al. 2010).  
In addition to its impact on Th17 cells, C5a may also regulate the development of Tregs 
(Palomares et al., 2010). Lack of C5aR signaling in mDCs results in Tregs differentiation 
(Lajoie et al.. 2010). Thus, C5aR signaling in APCs can modulate Th cell differentiation at 
several levels in allergic asthma. 
The development of asthma is not only regulated by C5a-C5aR/C5L2 interactions, but also 
by C3a-C3aR; however the role is less clear. In contrast to C5a, several studies suggest that 
C3a mainly contributes to the pathogenesis of asthma. When challenged with allergen, C3-
deficient mice exhibit diminished AHR and lung eosinophilia (Drouin et al., 2001). C3aR-
deficient mice challenged with Aspergillus fumigatus and OVA show attenuated/decreased 
AHR, airway eosinophilia, lung IL-4 producing cells, BALF levels of Th2 cytokines, serum 
IgE, and mucus production (Drouin et al., 2002). Similarly, C3a is also involved in the 
development of the late asthmatic response and AHR; the mechanism being related to the 
production of IL-1ǃ in the lung of OVA-challenged mice in response to C3a (Mizutani et al., 
2009). However, in a model of particulate matter-induced pulmonary allergy, C3-deficient 
mice develop dramatically reduced AHR, but they are not protected from airway 
inflammation (Walters et al., 2002). Similarly, OVA-sensitized C3aR-deficient mice show 
markedly reduced bronchoconstriction and AHR, but IgE production and Th2 cytokine 
levels remains the same when compared to WT mice (Humbles et al., 2000).  
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Differences in mice strains, nature of the allergens used for sensitization and route of 
allergen administration may account for the conflicting results generated in different animal 
models. The study by Zhang at al. compared Th2 immune responses in C5aR- and C3aR- 
deficient mice side-by-side. As mentioned earlier, in the absence of C5aR signaling HDM-
challenged mice suffer from an enhanced Th2 immune response. However, C3aR-deficient 
mice are protected against a Th2 immune response under same settings, delineating the 
opposing roles of C5aR and C3aR signaling in asthma. Interestingly, blocking C5aR-
mediated signaling in C3aR-deficient mice significantly increases AHR, airway eosinophilia, 
and Th2 cytokines production, indicating that the decreased Th2 immune response in the 
absence of C3aR signaling results from a shift towards protective C5aR signaling (Zhang et 
al., 2009). Cross-talk between the two receptors is further supported by the fact that C5a 
negatively regulates C3aR internalization. Pulmonary C5aR-deficient dendritic cells exhibit 
dramatically higher expression of C3aR in comparison to WT dendritic cells. In contrast, 
C5aR expression significantly decreases in HDM-pulsed WT dendritic cells, but less so in 
C3aR-deficient dendritic cells, further confirming that there is a reciprocal regulation 
between C5aR and C3aR (Settmacher et al., 1999).  
Recently, it has been shown that AHR, lung eosinophilia and mucus production are 
significantly increased in C5-deficient mouse model of Respiratory Syncytial Virus disease. 
C3aR expression in bronchial epithelial and smooth muscle cells of these mice are elevated 
as compared with WT mice. Ablation of C3aR signaling in C5-deficient mice significantly 
attenuates the disease phenotype, suggesting that C5 plays a crucial role in modulating 
AHR and eosinophilic inflammation by affecting expression of C3aR in the lungs (Melendi 
et al., 2007). C3a also has an impact on Th17 cell development. C3aR-deficient mice exhibit 
diminished AHR, fewer Th17 cells and decreased IL-17 compared to WT counterparts, 
which correlates with reduced IL-23 production. This suggests that unlike C5a, C3a 
mediates IL-23 production, IL-17 production and susceptibility to AHR (Lajoie et al., 2010). 
It is clear that in experimental models of allergic asthma, C5a-C5aR signaling seems to 
protect against the development of Th2 immune response during allergen exposure, 
whereas C3a-C3aR signaling contributes to the development of maladaptive immune 
responses. However, the strong evidence that suggests C5a and C3a synergistically 
contribute to the development of allergic inflammation and asthma can not be overlooked. 
As mentioned earlier, the contradictory nature of this evidence may be due to the fact that 
once allergic inflammation is established (effector phase of allergic asthma), both C3a and 
C5a act on circulating and tissue resident inflammatory immune cells such as mast cells, 
eosinophils, basophils, and lymphocytes leading to the induction of a pro-allergic immune 
response. Indeed, pharmacological targeting of C3aR and C5aR during the effector phase 
suppresses AHR, airway inflammation and Th2 cytokines production (Baelder et al., 2005). 
Thus, complement C3a and C5a, and their receptors display diverse activities during the 
course of disease progression. Reagents that specifically targets C3a, C3aR, C5, C5a or C5aR 
could serve as potential therapy for asthma.  
5.2 Sepsis 
Sepsis is a life-threatening medical condition characterized by dysregulated systemic 
inflammatory responses followed by immunosuppression. Despite advances in medical 
health care, sepsis remains one of the leading causes of death, accounting for more than 1.5 
million deaths annually in Europe and North America. Systemic inflammation in sepsis can 
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be triggered by various infectious agents, including bacteria (leading cause of sepsis), fungi, 
parasites and viruses. Over recent years, efforts to better understand the pathophysiology of 
sepsis, has given rise to enough convincing evidence to suggest that the activation of the 
complement system and production of C3a and C5a occurs in sepsis.  
Infectious agents activate the complement system through their interaction with C1q, MBL, 
or ficolins leading to local and/or systemic complement activation with subsequent 
production of C3a and C5a. Indeed, patients with sepsis syndrome show elevated plasma or 
serum levels of  C3a/C3a desArg, C4a and C5a/C5a desArg (Bengtson and Heideman, 1988, 
Cole et al., 2002, Nakae et al., 1994, Nakae et al., 1996, Selberg et al., 2000, Solomkin et al., 
1985, Weinberg et al., 1984), and circulating levels of C3a and C5a are inversely proportional 
to patient survival (Groeneveld et al., 2003, Hack et al., 1989, Hecke et al., 1997, Selberg et al., 
2000). In humans, C5a levels can rise as high as 100 nM (Ward, 2004).  
In vivo generation of C3a and C5a and their inflammatory effects in sepsis have been studied 
using three major animal models: a) intravenous injection of an exogenous toxin (e.g. 
anaphylatoxins); b) intravenous infusion of exogenous bacteria; and c) cecal ligation and 
puncture (CLP). Infusion of C5a into rabbits and rats produces the typical septic shock 
symptoms, including a rapid drop in mean arterial pressure and reduced circulation of 
granulocytes, monocytes and platelets in peripheral blood. Infusion of Escherichia coli (E. coli) 
in rabbits leads to severe septicemia with enhanced levels of C5a in the plasma, indicating 
that the degree of complement activation determines the severity of sepsis (Bergh et al., 
1991). Administration of an anti-C5a desArg antibody to E. coli-infused primates confers 
protection against mortality and attenuates systemic manifestations of sepsis (Stevens et al., 
1986), highlighting the importance of C5a in the septic shock pathology. Most of the studies 
dealing with the role of C5a in pathology of sepsis have been done using the rat and rodent 
models of CLP. This model of sepsis closely mimics the pathophysiology of sepsis in 
humans. Intravenous infusion of a neutralizing polyclonal antibody to rat C5a in CLP rats is 
highly protective, causing reduced evidence of multiorgan failure and resulting improved 
survival rates (from 0% survival in the unprotected to 50% survival in rats treated with an 
anti-C5a antibody). Moreover, CLP rats treated with an antibody against C5a show 
profound reduction (98% compared to unprotected rats) in bacterial colony forming units 
(CFUs), indicating that C5a is associated with the development of bacteremia in sepsis 
(Czermak et al., 1999).  
Successive studies with anti-C5a antibody-treated CLP rats and mice have further revealed 
that the survival rate of these animals depends on amount of antibody infused at the time of 
CLP, as well as the time of administration of the antibody. For instance, the infusion of 600 g 
of antibody targeted against the mid region of C5a remarkably improves survival in CLP 
rats (83-90% survival rate compared to 23% survival rate in CLP rats receiving pre-immune 
IgG or 100-220 g of anti-C5a antibody). Moreover, when 600 g of antibody is given at time 0 
of CLP, the survival rate is 90%; when infusion is delayed until 6 hr. post CLP, survival is 
around 60%; and when delayed until 12 hr. post CLP, the survival drops to 40% (Huber-
Lang et al., 2001). These results suggest that neutralization of C5a during a specific time 
window after the onset of sepsis may be efficacious in the treatment of sepsis. 
In sepsis, excessive production of C3a and C5a subsequently leads to dysfunction of 
neutrophils. Blood neutrophils display suppressed chemotactic responsiveness (Goya et al., 
1994, Solomkin et al., 1981), depressed enzyme release (Goya et al., 1994, Solomkin et al., 
1981, Utoh et al., 1989), alteration of intracellular pH (Sachse et al., 2000), and a defective 
respiratory burst (Czermak et al., 1999, Goya et al., 1994, Solomkin et al., 1981), resulting in 
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impaired bactericidal activity. For instance, during experimental sepsis, blood neutrophils 
show a decreased ability to bind C5a, impaired chemotactic response to C5a and a loss of 
H2O2-generating capacity. Exposure of rat neutrophils to C5a induces a defect in phagocytic 
function (Huber-Lang et al., 2002). Treatment of CLP rats with an anti-C5a antibody reverses 
these functional defects in neutrophils (Huber-Lang et al., 2002). Early after CLP, blood 
neutrophils from septic mice exhibit enhanced expression of the CC chemokine receptors 
(CCR1, CCR2, and CCR5) (Speyer et al., 2004), which may contribute to a stronger 
neutrophilic inflammatory response in sepsis. Moreover, CLP causes blood neutrophils to 
show an increased expression of ǃ1 integrins (CD29) and ǃ2 integrins (CD18), indicating a 
hyperresponsiveness to the receptors for these integrins (Guo et al., 2002). Collectively, this 
demonstrates that neutrophils develop an exaggerated response to various inflammatory 
mediators in the early stages of sepsis.  
Besides neutrophil dysfunction, C5a also affects other components of innate immunity 
leading to exacerbation of septicemia and immunosuppression. Systemic activation of 
complement in CLP model of sepsis induces C5a-dependent apoptosis of thymocytes (Guo 
et al., 2000), inducing a significant loss of thymus in first few days following CLP 
(Riedemann et al., 2002). C5aR expression on thymocytes rises rapidly after CLP and 
increased binding of C5a to CLP thymocytes can be found as early as 3 hr. post CLP. 
Administration of an anti-C5a neutralizing antibody at the time of CLP preserves the thymic 
mass and abolishes the apoptosis of thymocytes (Riedemann et al., 2002). Moreover, CLP in 
mice induces significant apoptosis of adrenomedullary cells 24 hr. post CLP, which is 
diminished after dual blockade of both C5aR and C5L2 (Flierl et al., 2008), indicating a role 
of C5a in multiorgan apoptosis during sepsis. C5a also promotes septic cardiomyopathy 
(Niederbichler et al., 2006) and consumptive coagulopathy (Laudes et al., 2002). The 
intensity of the coagulopathy of sepsis is greatly attenuated in CLP rats (for example, 
clotting times are minimally prolonged, thrombocytopenia is reduced and plasma levels of 
fibrin split products as well as thrombin-antithrombin complexes are greatly reduced) as a 
result of neutralization of C5a after CLP (Laudes et al., 2002). 
It seems clear that excessive C5a produced during sepsis has harmful effects, as described 
above and it is obvious that the effects are mediated via the interaction of C5a with its 
receptors. Indeed, experimental studies in animals with CLP suggest a dynamic balance 
between C5aR and C5L2 on immune cells and in organs. C5aR expression is markedly 
increased in lung, liver, kidney, and heart early in septic mice (Riedemann et al., 2002). C5L2 
mRNA is highly expressed in liver and thyroid of CLP rat, and weakly expressed in CLP rat 
brain, spleen, kidney, large intestine, eye as well as lung alveolar macrophages and 
peripheral blood neutrophils (Gao et al., 2005). Increased expression of C5aR and C5L2 in 
lung, liver, heart, and kidney after CLP-induced sepsis strongly implies the role of 
complement receptors in multiple organ failure.  
In vitro exposure of neutrophils to C5a reduces surface C5aR expression suggesting that 
following interaction C5a/C5aR complex undergo internalization, suggesting a possible 
cause for compromised neutrophil function (Huber-Lang et al., 2002).  During experimental 
sepsis C5aR content on blood neutrophils reduces 2.5-fold 24 hr. after CLP and increases 
steadily thereafter. On contrary, C5L2 content on blood neutrophils increases significantly 
24 and 36 hr. after onset of CLP. Moreover, confocal microscopy on blood neutrophils from 
CLP rats show cytoplasmic distribution of C5aR, but not C5L2, indicating that C5a/C5L2 
complex do not undergo internalization as C5a/C5aR after CLP (Gao et al., 2005), and that 
C5aR and C5L2 are independently regulated during sepsis. In presence of a cyclic peptide 
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antagonist (C5aRa) to the C5aR, the binding of C5a to mice peritoneal neutrophils is 
diminished, and the in vitro chemotactic response of neutrophils to C5a is decreased, C5a-
induced defect in the oxidative burst of neutrophils is reversed, and the lung vascular 
permeability index is markedly diminished. CLP mice treated with C5aRa show improved 
survival rates (from 10% survival in the sham to 60% survival in mice treated with C5aRa) 
(Huber-Lang et al., 2002). Using a combination of C5aR and C5L2 blocking antibodies, and 
mice lacking one of the two C5a receptors, considerable improvement in survival following 
CLP has been shown in a study by Rittirsch et al. In mid-grade CLP, WT, C5aR-deficient and 
C5L2-deficient mice show 31%, 80% and 100% survival by day 7, respectively, indicating 
harmful roles for both C5a receptors in the CLP model of sepsis. All WT mice show 100% 
and 80% survival after treatment with anti-C5aR and anti-C5L2 serum, respectively, 
compared to 40% survival in mice treated with preimmune serum. In high-grade CLP, none 
of the WT mice treated with preimmune serum, C5L2-deficient mice treated with anti-C5aR 
serum and C5aR-deficient mice survived. Interestingly, when C5L2-deficient mice are 
treated with anti-C5aR serum the survival rate improves significantly (80%). Similarly, 
treatment of C5aR-deficient mice with anti-C5L2 serum greatly improves survival (87% 
compared to 17% for C5aR-deficient mice treated with preimmune serum or 0% for WT 
mice treated with anti-C5L2 serum). Dual blockade of C5aR and C5L2 by a polyclonal 
antibody is also protective against the lethal outcome after high-grade CLP. Moreover, if the 
high-grade CLP mice are treated with anti-C5aR and anti-C5L2 serum after a delay of 12 hr. 
or 24 hr. post CLP there is no protective effect against mortality. The combined blockade of 
the C5a receptors during sepsis is most effective when given before the onset of sepsis. In 
summary, both C5aR and C5L2 contribute cooperatively to mortality in sepsis. Evaluation of 
plasma cytokine and chemokine concentrations after CLP shows a reduction in the levels of 
IL-1ǃ, MIP-1ǂ, and MIP-2 in C5aR-deficient and C5L2-deficient mice in comparison to WT 
mice. However, the plasma concentration of IL-6 is significantly increased in C5L2-deficient 
CLP mice in comparison to WT mice. In contrast, plasma IL-6 is markedly reduced in C5aR-
deficient CLP mice when compared to WT mice, as observed by Gao et al. (Gao et al., 2005), 
suggesting that the sepsis-induced cytokine and chemokine production may occur in a 
sequential fashion which requires C5a engagement of both C5a receptors. Another 
important observation obtained from this study is that C5L2-deficient CLP mice have 
greatly reduced levels of high-mobility group protein 1 (HMGB1, a late mediator in sepsis) 
in plasma. Interestingly, CLP in C5aR-deficient CLP mice has no effect on plasma HMGB1 
levels when compared to WT CLP mice. Furthermore, C5a-stimulated macrophages from 
WT and C5aR-deficient mice produce significant amounts of HMGB1, whereas C5a-
stimulated macrophages from C5L2-deficient mice produce very little HMGB1 (Rittirsch et 
al., 2008), supporting the fact that C5a mediates the pathophysiology of sepsis by acting on 
C5a receptors and that C5L2 has a functional role in sepsis.  
Recently, a study has shown that ǄǅT cells are involved in the pathogenesis of sepsis by 
producing large amounts of IL-17 (Xu et al., 2010), express C5aR, and the expression of C5aR 
increases in mice following sepsis. Neutralization of C5a partially prevents the upregulation of 
C5aR on ǄǅT cells in septic mice. Furthermore, C5a promotes the IL-17 expression by ǄǅT cells 
which can be attenuated by blocking PI3K/Akt signaling pathway, demonstrating that C5a 
acts on C5aR expressed on ǄǅT cells, resulting in the pathophysiology of sepsis (Han et al.).  
In summary, C5a binding to C5aR and C5L2 receptors seem to contribute to cytokine storm, 
associated multiple organ dysfunction and subsequent lethal outcome in the setting of 
experimental sepsis. C5aR and C5L2 both contribute synergistically to the harmful events in 
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sepsis. A maximal beneficial effect can be achieved by the blockade or absence of both 
receptors, which might have implication in complement-based therapy for inflammatory 
diseases.   
5.3 Chronic urticaria 
Chronic urticaria is a debilitating skin condition characterized by the near daily occurrence 
of pruritic wheals for at least six weeks (Kaplan, 2004). While the pathogenesis of chronic 
urticaria is not completely understood, mast cell and basophils degranulation and histamine 
release are believed to be of central importance. Recent studies suggest that this activation of 
mast cells and basophils could in part be initiated by the C3a and C5a or these complement 
proteins can augment allergen-antibody mediated cell activation. Indeed, heating serum 
from patients with chronic urticaria, which heat-inactivates complement proteins, reduces 
the ability of serum to induce histamine release from basophils. Similarly, decomplemented 
sera deficient in C5 is incapable of releasing histamine from dermal mast cells (Kikuchi and 
Kaplan, 2002).  
C5a may play a key role in the pathogenesis of chronic urticaria as it can degranulate mast 
cells and basophils following its interaction with the C5aR present on these cells (Fureder et 
al., 1995). C5a can also chemoattract neutrophils, basophils, eosinophils and mast cells, 
which are present in chronic urticaria lesions. Korosec et al. showed that patients with 
chronic urticaria have enhanced basophil activation in response to C5a. However, C5aR 
antagonist-treated serum from these patients show decreased histamine release from 
basophil. Furthermore, the release of histamine from basophils by anti-FcǆRI autoantibodies 
can be augmented by C5a activation (Korosec et al., 2009). Taken together these studies 
suggest that complement proteins and their receptors contribute towards the pathology of 
chronic urticaria.  
5.4 Cancer 
The complement system has also been well recognized as a promoter of tumor 
development. The deposition of complement component C3 is associated with the tumor 
vasculature in mice; C3-deficient mice show reduced tumor growth. The anaphylatoxin C5a 
promotes the growth of malignant tumors in a mouse model of cervical carcinoma. C5aR-
deficient mice treated with a C5a antagonist exhibit reduced tumor growth, as well as 
enhanced infiltration of tumor tissue with CD8+ cytotoxic T cells in comparison to WT mice, 
suggesting that C5a promotes tumor growth by inhibiting the response of CD8+ cytotoxic T 
cells against tumors. Elimination of CD8+ cytotoxic T cells from C5aR-deficient increases the 
rate of tumor growth, confirming that C5a modulates the CD8+ T cells-mediated anti-tumor 
immune responses (Markiewski et al., 2008).  
The interplay between CD8+ cytotoxic T cells and myeloid-derived suppressor cells 
(MDSCs) play a significant role in determining the fate of tumors. MDSCs are a 
heterogeneous population of regular myeloid cells, also referred to as immature 
counterparts of monocytes and neutrophils, which express C5aR. C5aR is partially 
internalized in tumor-associated MDSCs, suggesting that MDSCs are constantly exposed to 
and activated by C5a generated in the tumor microenvironment. C5a chemoattracts MDSCs 
to the tumor, partly by upregulating adhesion molecules on MDSCs. C5a also enhances the 
production of ROS and reactive nitrogen species (RNS) from MDSC, which are known to 
suppress CD8+ cytotoxic T cell anti-tumor responses. C5aR-deficient mice or mice treated 
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with a C5aR antagonist show reduced numbers of MDSCs within the tumor tissue, 
increased numbers of CD8+ cytotoxic T cells and decreased tumor growth. MDSCs from 
C5a-deficient mice are unable to inhibit T cell proliferation in vivo (Markiewski et al., 2008). 
These observations highlight the potential of anaphylatoxins and their receptors as novel 
targets for anti-cancer immunotherapy.  
5.5 Ischemia-reperfusion injury 
Ischemia-reperfusion (I/R) injury is defined as cellular injury occurring after the reperfusion 
of previously vascularised tissue following an extended period of ischemia. The 
augmentation of tissue injury after reperfusion results from an intense inflammatory 
response that develops simultaneously with tissue reperfusion (Eltzschig and Collard, 2004). 
Several pathological conditions can lead to I/R injury including myocardial infarction, 
stroke, hemorrhagic shock, severe trauma, and organ transplantation resulting in associated 
morbidity and mortality (Eltzschig and Collard, 2004).  
Numerous studies have shown that ischemic tissue activates the complement system, which 
remarkably contributes to the development of tissue damage by enhancing inflammation 
(Hart et al., 2004). The first evidence for involvement of complement in I/R injury was 
proposed by Hill and Ward in 1971 (Hill and Ward, 1971). During I/R injury the 
complement system can be activated by the classical, alternative, and lectin pathways. For 
instance, skeletal muscle injury resulting from I/R likely occurs through the complement 
activation via the classical and lectin pathways (Weiser et al., 1996). Lectin pathway may be 
involved in myocardial (Jordan et al., 2001) and gastrointestinal I/R-induced complement 
activation (Hart et al., 2004). However, the amplification of complement activation in 
gastrointestinal I/R occurs through the alternative pathway (Hart et al., 2004). Alternative 
pathway of complement activation may contribute to renal I/R injury in mice (Thurman et 
al., 2003).  
Studies suggest that complements C3a and C5a are major complement factors responsible 
for the induction of the reperfusion-associated inflammatory response. C3a and C5a activate 
endothelial cells and inflammatory leukocytes. C5a upregulates the expression of adhesion 
molecules on human umbilical vein endothelial cells (Foreman et al., 1996) and induces 
release of various cytokines, including IL-1, IL-6, MCP-1, and TNFǂ (Schindler et al., 1990). 
C5aR expression is upregulated following cold I/R injury in a mouse model of syngenic 
kidney transplantation, suggesting that C5aR may contribute to tissue damage, tubular 
apoptosis and dysfunction of donor organs. Furthermore, upregulation of C5aR expression 
in cadaveric kidneys correlates with cold ischemia time. Ablation of C5aR signaling during 
cold ischemia has a protective effect on kidney graft survival (Lewis et al., 2008). Animals 
treated with a C5aR antagonist show dramatically reduced accumulation of neutrophils in 
the post-ischemic livers and sustain less injury during reperfusion (Arumugam et al., 2003). 
In a mouse model of I/R muscle injury, mice treated with a C5aR antagonist exhibit 
decreased levels of circulating creatinine kinase, lactate dehydrogenase, alanine and 
aspartate aminotransferase, creatinine, blood urea nitrogen, muscle edema, lung and liver 
myeloperoxidase, and lung TNFǂ following hind limb injury (Woodruff et al., 2004).  
Studies targeting C5a/C5aR complex have further confirmed the role played by C5a in the 
pathogenesis of I/R injury. Blocking C5aR signaling using an anti-C5aR antibody markedly 
decreases leukocyte adherence, microvascular permeability in the ischemic myocardial area 
(Zhang et al., 2007), myocardial neutrophil infiltration and arteriolar endothelial injury 
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(Park et al., 1999). Knocking down C5aR expression with small interference (si)RNA 
preserves renal function from I/R injury, reduces chemokine production and neutrophil 
infiltration (Zheng et al., 2008). Treatment with an anti-C5 neutralizing antibody reduces 
apoptosis and necrosis in heart allografts (Ferraresso et al., 2008).  
In contrast to C5a, the role of C3a/C3aR in I/R injury is not properly established. Systemic 
inhibition of C3a with a C3aR antagonist minimally resolves myocardial I/R injury, and 
neutropenia rather than C3aR antagonism appears to be responsible for C3aR antagonist-
associated improvement in myocardial I/R injury (Busche and Stahl, 2010). These results 
confirm similar observations from previous studies (Ames et al., 2001, Proctor et al., 2004), 
indicating that C3aR antagonist-mediated neutrophil tissue sequestration during I/R injury 
may account for the protective effects observed. Overall, the data indicate while C3a/C3aR 
inhibition in the clinical setting of I/R injury does not appear to be therapeutic, targeting 
C5a as well as C5aR may be a promising approach to prevent I/R injury. 
5.6 Transplantation 
The activation products of complement system play an important role in allograft rejection 
as evidenced by the fact that the lack of C3 in donor kidneys is associated with long-term 
graft survival in experimental transplantation (Pratt et al., 2002). A study in human kidney 
transplantation has shown that donor C3 polymorphisms are associated with late graft 
failure. Thus donor expression of C3 influences the alloimmune response and the fate of the 
transplantation (Brown et al., 2006). APCs are the source of C3 and macrophages from C3-
deficient mice have an impaired potency to stimulate alloreactive T cell response and to 
drive Th1-biased adaptive immune responses supporting graft survival (Peng et al., 2006, 
Zhou et al., 2006). It is now clear that this effect of C3 is mediated via the interaction of 
C3a with the C3aR on APCs. C3a-deficient dendritic cells show reduced surface 
expression of major histocompatibility complex (MHC) class II and co-stimulatory 
molecules and elicit a defective T cell priming against alloantigen expressed on the 
dendritic cells (Peng et al., 2008). Mechanistically, C3a-C3aR interaction on surface of 
dendritic cells decreases the level of intracellular cAMP, which in turn promotes allergen 
uptake and T cell priming (Li et al., 2008).  
As mentioned in previous section, complement activation is critically involved in I/R injury; 
C5a and C5aR blockade has been shown attenuate organ damage, improve graft function 
and transplantation outcome. In human kidney transplants with acute rejection, C5aR 
expression is increased in renal tissue and in cells infiltrating the tubulointerstitium.  
Treatment of recipient mice with a C5aR antagonist before transplantation markedly 
improves renal allograft survival and reduces alloreactive T cell priming. Similarly, 
inhibition of C5aR in murine model of renal allotransplantation substantially improved graft 
survival from 11 days to 12 weeks. In addition, C5aR inhibition reduces kidney 
inflammation, apoptosis, and priming of alloreactive T cells (Gueler et al., 2008). 
Pharmacological targeting of C5aR during organ preservation significantly improves kidney 
graft survival (Lewis et al., 2008). Baboons treated with an anti-C5a monoclonal antibody 
exhibit prolonged pulmonary xenografts survival, indicating that C5a exacerbates 
pulmonary xenografts injury (Gaca et al., 2006). A recent study by Vieyra et al. have shown 
that dendritic cell-derived C3a and C5a regulates CD4+ T cell help to CD8+ T cell responses 
required for murine allograft rejection (Vieyra et al., 2011). These results demonstrate that 
C3aR and C5aR signaling contribute towards the innate and adaptive inflammatory 
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responses following solid organ transplantation, suggesting that pharmaceutical targeting of 
C3aR and C5aR may have an application in transplantation medicine.  
5.7 Stroke 
Stroke is the second leading cause of death worldwide, which is defined as a rapidly 
developing loss of brain function(s) due to inadequate blood flow in a localized area. When 
blood flow is interrupted to part of the brain, brain cells quickly begin to die leading to 
stroke development. There are many elements that contribute to the development of stroke, 
of which neuroinflammation is a major one. However, the precise roles of various pro-
inflammatory mediators, including cytokines, chemokines and immune cells, are still largely 
unknown. Increasing evidence suggests that the activation of the complement cascade 
contributes to pathological inflammatory events in brain (upregulation of adhesion 
molecules, immune cell activation, chemotaxis, expression of IL-8 and MCP-1 by endothelial 
cells) (D'Ambrosio et al., 2001), resulting in ischemic insult, neurodegeneration and stroke 
development.  
Following brain I/R injury ROS, RNS as well as oxygen free radicals are generated by 
activated brain cells and infiltrating immune cells, which stimulate stroke-associated brain 
injury (Elsner et al., 1994, McColl et al., 2009). Brain cells such as astrocytes, microglia, 
neurons, and endothelial cells and infiltrating immune cells produce various pro-
inflammatory mediators following ischemia, further contributing towards cell death (Yilmaz 
et al., 2006). Ischemic stroke enhances interaction between endothelial cells, brain cells, and 
immune cells that may aggravate the injury process (Urra et al., 2009). All these stroke-
associated brain pathologies are function of C3a-C3aR and C5a-C5aR interactions 
(D'Ambrosio et al., 2001). Strong C3a and C5a activation is observed in patients with acute 
ischemic stroke, which correlates with disease severity (Szeplaki et al., 2009). Regional brain 
I/R injury induces an inflammatory reaction that involves generation of C3a and C5a, 
upregulation and enhanced activation of their receptors C3aR and C5aR.  
In the brain, C3aR and C5aR are expressed by astrocytes (Gasque et al., 1995, Gasque et al., 
1997, Gasque et al., 1998, Lacy et al., 1995, Sayah et al., 1997), glial cells (Davoust et al., 1999, 
Gasque et al., 1997, Lacy et al., 1995) and neurons (Davoust et al., 1999). Experimental 
models of permanent and transient middle cerebral artery occlusion (MCAO) have 
demonstrated an increase in the expression of complement receptors. The expression of 
C3aR and C5aR is enhanced in mouse ischemic cortex following permanent MCAO. In 
addition, the expression is also induced on endothelial cells within ischemic core, suggesting 
that the complement receptors are important in leukocyte recruitment and 
neuroinflammation (Van Beek et al., 2000). Expression of C3aR and C5aR is significantly 
increased after transient MCAO in rats (Nishino et al., 1994) and mice (Barnum et al., 2002). 
In the later study, C5aR expression dramatically increases within 3 hr. after MCAO, whereas 
C3aR expression reduces to 25% of control animals. By 24 hr. post-occlusion, expression of 
both receptors is highest. This increased expression at the later time points after occlusion is 
most likely the result of a massive infiltration of immune cells expressing C3aR and C5aR 
(Barnum et al., 2002).  
Early attempts at complement inhibition using cobra venom factor (CVF) have further 
revealed that abrogation of the complement system can provide protection for the brain 
during I/R injury and stroke. Pretreatment of rats with CVF (complement-depleted rats) 
prior to temporary cerebral ischemia significantly enhances the magnitude of reactive 
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hyperemia and increases preservation of somatosensory evoked potentials (SSEPs), 
demonstrating that depleting the complement system can improve blood flow and clinical 
outcome following cerebral I/R (Vasthare et al., 1998). Similarly, complement depletion via 
CVF significantly reduces post-ischemic cerebral infarct volume in adult rats and post-
hypoxic-ischemic cerebral atrophy in neonates (Figueroa et al., 2005). However, the lack of 
specificity of CVF did not give any information regarding complement components that are 
most relevant in the pathogenesis of brain injury and stroke.  
Recent studies using genetic knockouts of C3 and C5 and inhibitors of C3a-C3aR, and C5a-
C5aR signaling have better our understanding of the role of anaphylatoxins in stroke. C3-
deficient mice are protected against cerebral I/R injury, as demonstrated by significant 
reductions in both infarct volume and neurological deficit score. C3-deficient mice also 
exhibit diminished granulocyte infiltration and oxidative stress. The administration of a 
C3aR antagonist reduces stroke volume leading to neurological improvement (Mocco et al., 
2006), implicating the involvement of C3a and C3aR in acute stroke. Studies with genetic 
knockouts of C5 in stroke have yielded conflicting data. C5-deficient animals show 
increased vulnerability to intracerebral hemorrhage (ICH) (Nakamura et al., 2004) and 
ischemic stroke (Mocco et al., 2006). In contrast, C5-deficient mice subjected to brain I/R 
injury exhibits improved functional outcome and less brain damage (Arumugam et al., 
2007). A recent study by Rynkowski et al. have shown that blocking C3a-mediated signaling 
using a C3aR antagonist is protective in a mouse model if ICH (Rynkowski et al., 2009). 
Similarly, mice treated with C5aR antagonist alone or C3aR and C5aR antagonists exhibit 
improvement in neurological functions following ICH, suggesting that blockade of C3aR 
and C5aR represents a promising therapeutic strategy in stroke.  
6. Conclusion 
The complement system is composed of a network of proteins that play an important role in 
innate and adaptive immunity. Originally discovered as antimicrobial agents, the main 
function of C3a and C5a was considered to be the opsonization of pathogens and 
chemoattraction to remove apoptotic and necrotic cells. However, today complement 
proteins, C3a and C5a, are considered as crucial immunoregulatory molecules with 
pleiotropic biological functions on immune cells which help to shape the immune response. 
Activation of complement system is exquisitely regulated, while improper activation or 
under certain conditions the effect can lead to adverse consequences. Similar to 
dysregulation of the adaptive immune system in hypersensitivity reactions, the pathological 
role of C3a, C5a and their receptors in inflammatory diseases as well as tumor growth is 
well defined. Due to their strong inflammatory properties, C3a/C3aR and C5a/C5aR are 
considered attractive pharmacological targets for the development of therapeutic agents. 
Given that many therapeutic agents targeting the interaction of C3a-C3aR and C5a-C5aR are 
already under investigation, the advances made in the field of complement and complement 
receptors discussed in this book chapter will better our understanding of the disease process 
and help develop new therapeutic approaches to modulate immune response 
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